ID   TRIB1_HUMAN             Reviewed;         372 AA.
AC   Q96RU8; B4DMM6; C5HU08; O15180; Q9H2Y8;
DT   06-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   06-DEC-2005, sequence version 2.
DT   12-OCT-2022, entry version 167.
DE   RecName: Full=Tribbles homolog 1;
DE            Short=TRB-1;
DE   AltName: Full=G-protein-coupled receptor-induced gene 2 protein;
DE            Short=GIG-2;
DE   AltName: Full=SKIP1;
GN   Name=TRIB1 {ECO:0000312|HGNC:HGNC:16891};
GN   Synonyms=C8FW {ECO:0000312|EMBL:CAA04119.1}, GIG2
GN   {ECO:0000312|EMBL:AAG35663.1}, TRB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAK58174.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND
RP   INTERACTION WITH MAP2K1 AND MAP2K4.
RX   PubMed=15299019; DOI=10.1074/jbc.m407732200;
RA   Kiss-Toth E., Bagstaff S.M., Sung H.Y., Jozsa V., Dempsey C., Caunt J.C.,
RA   Oxley K.M., Wyllie D.H., Polgar T., Harte M., O'Neill L.A.J.,
RA   Qwarnstrom E.E., Dower S.K.;
RT   "Human tribbles, a protein family controlling mitogen-activated protein
RT   kinase cascades.";
RL   J. Biol. Chem. 279:42703-42708(2004).
RN   [2] {ECO:0000312|EMBL:AAG35663.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RA   Mayhaus M., von der Kammer H., Klaudiny J., Albrecht C., Hoffmann B.,
RA   Nitsch R.M.;
RT   "Identification of a novel nuclear factor Gig2, as an m1-acetylcholine
RT   receptor-induced gene.";
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph node;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5] {ECO:0000312|EMBL:AAG35663.1}
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7] {ECO:0000312|EMBL:AAG35663.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8] {ECO:0000312|EMBL:AAH63292.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta {ECO:0000312|EMBL:AAH63292.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9] {ECO:0000305, ECO:0000312|EMBL:CAA04119.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 149-372 (ISOFORM 1).
RC   TISSUE=Thyroid {ECO:0000312|EMBL:CAA04119.1};
RX   PubMed=9342215; DOI=10.1111/j.1432-1033.1997.t01-1-00660.x;
RA   Wilkin F., Suarez-Huerta N., Robaye B., Peetermans J., Libert F.,
RA   Dumont J.E., Maenhaut C.;
RT   "Characterization of a phosphoprotein whose mRNA is regulated by the
RT   mitogenic pathways in dog thyroid cells.";
RL   Eur. J. Biochem. 248:660-668(1997).
RN   [10]
RP   INTERACTION WITH CEBPA AND COP1.
RX   PubMed=20410507; DOI=10.1182/blood-2009-07-229450;
RA   Dedhia P.H., Keeshan K., Uljon S., Xu L., Vega M.E., Shestova O.,
RA   Zaks-Zilberman M., Romany C., Blacklow S.C., Pear W.S.;
RT   "Differential ability of Tribbles family members to promote degradation of
RT   C/EBPalpha and induce acute myelogenous leukemia.";
RL   Blood 116:1321-1328(2010).
RN   [11] {ECO:0007744|PDB:5CEK, ECO:0007744|PDB:5CEM}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 83-371, FUNCTION, INTERACTION
RP   WITH CEBPA, AND SUBUNIT.
RX   PubMed=26455797; DOI=10.1016/j.str.2015.08.017;
RA   Murphy J.M., Nakatani Y., Jamieson S.A., Dai W., Lucet I.S., Mace P.D.;
RT   "Molecular mechanism of CCAAT-enhancer binding protein recruitment by the
RT   TRIB1 pseudokinase.";
RL   Structure 23:2111-2121(2015).
RN   [12] {ECO:0007744|PDB:5IGO, ECO:0007744|PDB:5IGQ}
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 354-361, INTERACTION WITH COP1,
RP   DOMAIN, AND MUTAGENESIS OF ASP-355; GLN-356; ILE-357; VAL-358; PRO-359;
RP   GLU-360 AND TYR-361.
RX   PubMed=27041596; DOI=10.1016/j.str.2016.03.002;
RA   Uljon S., Xu X., Durzynska I., Stein S., Adelmant G., Marto J.A.,
RA   Pear W.S., Blacklow S.C.;
RT   "Structural basis for substrate selectivity of the E3 ligase COP1.";
RL   Structure 24:687-696(2016).
RN   [13]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-173; MET-215; ILE-267; CYS-298;
RP   ALA-360; ASP-360 AND LEU-371.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Adapter protein involved in protein degradation by
CC       interacting with COP1 ubiquitin ligase (PubMed:27041596). The COP1-
CC       binding motif is masked by autoinhibitory interactions with the protein
CC       kinase domain (PubMed:26455797). Serves to alter COP1 substrate
CC       specificity by directing the activity of COP1 toward CEBPA
CC       (PubMed:27041596). Binds selectively the recognition sequence of CEBPA
CC       (PubMed:26455797). Regulates myeloid cell differentiation by altering
CC       the expression of CEBPA in a COP1-dependent manner (By similarity).
CC       Controls macrophage, eosinophil and neutrophil differentiation via the
CC       COP1-binding domain (By similarity). Interacts with MAPK kinases and
CC       regulates activation of MAP kinases, but has no kinase activity
CC       (PubMed:15299019, PubMed:26455797). {ECO:0000250|UniProtKB:Q8K4K4,
CC       ECO:0000269|PubMed:15299019, ECO:0000269|PubMed:26455797,
CC       ECO:0000305|PubMed:27041596}.
CC   -!- SUBUNIT: Monomer (PubMed:26455797). Interacts (via protein kinase
CC       domain) with CEBPA (PubMed:20410507, PubMed:26455797). Interacts with
CC       COP1 (PubMed:20410507, PubMed:27041596). {ECO:0000269|PubMed:20410507,
CC       ECO:0000269|PubMed:26455797, ECO:0000269|PubMed:27041596}.
CC   -!- INTERACTION:
CC       Q96RU8; Q8N2I9: STK40; NbExp=4; IntAct=EBI-492555, EBI-716112;
CC       Q96RU8-1; P49715-1: CEBPA; NbExp=2; IntAct=EBI-16180744, EBI-16180754;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96RU8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96RU8-2; Sequence=VSP_054894;
CC   -!- TISSUE SPECIFICITY: Expressed in most human tissues with the highest
CC       levels in skeletal muscle, thyroid gland, pancreas, peripheral blood
CC       leukocytes, and bone marrow. {ECO:0000269|PubMed:15299019}.
CC   -!- DOMAIN: The protein kinase active site is incompatible with ATP binding
CC       and is inactive (PubMed:26455797). {ECO:0000269|PubMed:26455797}.
CC   -!- DOMAIN: The C-terminus (351-372) is required for interaction with COP1
CC       (PubMed:27041596). {ECO:0000269|PubMed:27041596}.
CC   -!- DOMAIN: The COP1-binding motif (355-360) is required for regulation
CC       activity (By similarity). {ECO:0000250|UniProtKB:Q8K4K4}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. Tribbles subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF250310; AAK58174.1; -; mRNA.
DR   EMBL; AF205437; AAG35663.1; -; mRNA.
DR   EMBL; AK297539; BAG59938.1; -; mRNA.
DR   EMBL; AL832388; CAI46181.1; -; mRNA.
DR   EMBL; FJ515869; ACS13752.1; -; Genomic_DNA.
DR   EMBL; AC091114; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471060; EAW92085.1; -; Genomic_DNA.
DR   EMBL; BC063292; AAH63292.1; -; mRNA.
DR   EMBL; AJ000480; CAA04119.1; -; mRNA.
DR   CCDS; CCDS6357.1; -. [Q96RU8-1]
DR   CCDS; CCDS64971.1; -. [Q96RU8-2]
DR   RefSeq; NP_001269914.1; NM_001282985.1. [Q96RU8-2]
DR   RefSeq; NP_079471.1; NM_025195.3. [Q96RU8-1]
DR   PDB; 5CEK; X-ray; 2.80 A; A=83-343.
DR   PDB; 5CEM; X-ray; 2.10 A; A=83-371.
DR   PDB; 5IGO; X-ray; 1.60 A; U/V/W/X=354-361.
DR   PDB; 5IGQ; X-ray; 3.90 A; U=354-364, V/W/X/Y/Z=354-361.
DR   PDB; 6DC0; X-ray; 2.80 A; A/B=90-343.
DR   PDBsum; 5CEK; -.
DR   PDBsum; 5CEM; -.
DR   PDBsum; 5IGO; -.
DR   PDBsum; 5IGQ; -.
DR   PDBsum; 6DC0; -.
DR   AlphaFoldDB; Q96RU8; -.
DR   SMR; Q96RU8; -.
DR   BioGRID; 115516; 43.
DR   DIP; DIP-34542N; -.
DR   IntAct; Q96RU8; 26.
DR   MINT; Q96RU8; -.
DR   STRING; 9606.ENSP00000312150; -.
DR   ChEMBL; CHEMBL4524042; -.
DR   iPTMnet; Q96RU8; -.
DR   PhosphoSitePlus; Q96RU8; -.
DR   BioMuta; TRIB1; -.
DR   DMDM; 83305929; -.
DR   EPD; Q96RU8; -.
DR   jPOST; Q96RU8; -.
DR   MassIVE; Q96RU8; -.
DR   MaxQB; Q96RU8; -.
DR   PaxDb; Q96RU8; -.
DR   PeptideAtlas; Q96RU8; -.
DR   PRIDE; Q96RU8; -.
DR   ProteomicsDB; 4625; -.
DR   ProteomicsDB; 78041; -. [Q96RU8-1]
DR   Antibodypedia; 27210; 387 antibodies from 31 providers.
DR   DNASU; 10221; -.
DR   Ensembl; ENST00000311922.4; ENSP00000312150.3; ENSG00000173334.4. [Q96RU8-1]
DR   Ensembl; ENST00000520847.1; ENSP00000429063.1; ENSG00000173334.4. [Q96RU8-2]
DR   GeneID; 10221; -.
DR   KEGG; hsa:10221; -.
DR   MANE-Select; ENST00000311922.4; ENSP00000312150.3; NM_025195.4; NP_079471.1.
DR   UCSC; uc003yrx.4; human. [Q96RU8-1]
DR   CTD; 10221; -.
DR   DisGeNET; 10221; -.
DR   GeneCards; TRIB1; -.
DR   HGNC; HGNC:16891; TRIB1.
DR   HPA; ENSG00000173334; Tissue enhanced (bone).
DR   MIM; 609461; gene.
DR   neXtProt; NX_Q96RU8; -.
DR   OpenTargets; ENSG00000173334; -.
DR   PharmGKB; PA134963922; -.
DR   VEuPathDB; HostDB:ENSG00000173334; -.
DR   eggNOG; KOG0583; Eukaryota.
DR   GeneTree; ENSGT00950000182986; -.
DR   HOGENOM; CLU_000288_13_1_1; -.
DR   InParanoid; Q96RU8; -.
DR   OMA; KEPWERL; -.
DR   OrthoDB; 1362510at2759; -.
DR   PhylomeDB; Q96RU8; -.
DR   TreeFam; TF329785; -.
DR   PathwayCommons; Q96RU8; -.
DR   Reactome; R-HSA-9031628; NGF-stimulated transcription.
DR   SignaLink; Q96RU8; -.
DR   BioGRID-ORCS; 10221; 35 hits in 1115 CRISPR screens.
DR   ChiTaRS; TRIB1; human.
DR   GeneWiki; TRIB1; -.
DR   GenomeRNAi; 10221; -.
DR   Pharos; Q96RU8; Tbio.
DR   PRO; PR:Q96RU8; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q96RU8; protein.
DR   Bgee; ENSG00000173334; Expressed in mucosa of urinary bladder and 196 other tissues.
DR   ExpressionAtlas; Q96RU8; baseline and differential.
DR   Genevisible; Q96RU8; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0031434; F:mitogen-activated protein kinase kinase binding; IDA:BHF-UCL.
DR   GO; GO:0004860; F:protein kinase inhibitor activity; IMP:BHF-UCL.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISS:BHF-UCL.
DR   GO; GO:0055106; F:ubiquitin-protein transferase regulator activity; ISS:BHF-UCL.
DR   GO; GO:0007254; P:JNK cascade; IMP:BHF-UCL.
DR   GO; GO:0043433; P:negative regulation of DNA-binding transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0031665; P:negative regulation of lipopolysaccharide-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0045659; P:negative regulation of neutrophil differentiation; IEA:Ensembl.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IMP:BHF-UCL.
DR   GO; GO:0014912; P:negative regulation of smooth muscle cell migration; IMP:BHF-UCL.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0045645; P:positive regulation of eosinophil differentiation; IEA:Ensembl.
DR   GO; GO:0045651; P:positive regulation of macrophage differentiation; IEA:Ensembl.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISS:BHF-UCL.
DR   GO; GO:0043405; P:regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IMP:BHF-UCL.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR024105; TRB1.
DR   InterPro; IPR024104; Tribbles/Ser_Thr_kinase_40.
DR   PANTHER; PTHR22961; PTHR22961; 1.
DR   PANTHER; PTHR22961:SF17; PTHR22961:SF17; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Protein kinase inhibitor;
KW   Reference proteome.
FT   CHAIN           1..372
FT                   /note="Tribbles homolog 1"
FT                   /id="PRO_0000131859"
FT   DOMAIN          1..338
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..23
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          52..86
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           355..360
FT                   /note="COP1-binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4K4"
FT   COMPBIAS        59..76
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VAR_SEQ         1..166
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054894"
FT   VARIANT         173
FT                   /note="S -> R (in dbSNP:rs56285697)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042364"
FT   VARIANT         215
FT                   /note="T -> M (in dbSNP:rs34349706)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042365"
FT   VARIANT         267
FT                   /note="V -> I (in dbSNP:rs56056430)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042366"
FT   VARIANT         298
FT                   /note="R -> C (in dbSNP:rs55953723)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042367"
FT   VARIANT         360
FT                   /note="E -> A (in dbSNP:rs35454769)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042368"
FT   VARIANT         360
FT                   /note="E -> D (in dbSNP:rs16900603)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042369"
FT   VARIANT         371
FT                   /note="F -> L (in a lung large cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042370"
FT   MUTAGEN         355
FT                   /note="D->A: Decreased interaction with COP1."
FT                   /evidence="ECO:0000269|PubMed:27041596"
FT   MUTAGEN         356
FT                   /note="Q->A: Decreased interaction with COP1."
FT                   /evidence="ECO:0000269|PubMed:27041596"
FT   MUTAGEN         357
FT                   /note="I->A: Decreased interaction with COP1."
FT                   /evidence="ECO:0000269|PubMed:27041596"
FT   MUTAGEN         358
FT                   /note="V->I,A: Loss of interaction with COP1."
FT                   /evidence="ECO:0000269|PubMed:27041596"
FT   MUTAGEN         359
FT                   /note="P->A: Strongly decreased interaction with COP1."
FT                   /evidence="ECO:0000269|PubMed:27041596"
FT   MUTAGEN         360
FT                   /note="E->A: Decreased interaction with COP1."
FT                   /evidence="ECO:0000269|PubMed:27041596"
FT   MUTAGEN         361
FT                   /note="Y->A: No effect on interaction with COP1."
FT                   /evidence="ECO:0000269|PubMed:27041596"
FT   CONFLICT        149..150
FT                   /note="VI -> SV (in Ref. 9; CAA04119)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        163
FT                   /note="D -> S (in Ref. 1 and 9)"
FT                   /evidence="ECO:0000305"
FT   STRAND          89..91
FT                   /evidence="ECO:0007829|PDB:5CEK"
FT   STRAND          94..98
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   STRAND          103..110
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   TURN            111..113
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   STRAND          116..123
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   HELIX           124..130
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   HELIX           132..135
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   STRAND          137..139
FT                   /evidence="ECO:0007829|PDB:5CEK"
FT   TURN            141..143
FT                   /evidence="ECO:0007829|PDB:5CEK"
FT   STRAND          146..151
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   STRAND          153..160
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   HELIX           167..174
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   HELIX           179..198
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   HELIX           208..210
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   STRAND          211..215
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   STRAND          221..223
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   STRAND          240..243
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   HELIX           246..248
FT                   /evidence="ECO:0007829|PDB:6DC0"
FT   HELIX           251..254
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   HELIX           262..279
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   HELIX           289..297
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   STRAND          305..307
FT                   /evidence="ECO:0007829|PDB:5CEK"
FT   HELIX           309..318
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   HELIX           323..325
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   HELIX           329..332
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   HELIX           336..341
FT                   /evidence="ECO:0007829|PDB:5CEM"
FT   STRAND          360..362
FT                   /evidence="ECO:0007829|PDB:5CEM"
SQ   SEQUENCE   372 AA;  41009 MW;  5F54E50924B1365B CRC64;
     MRVGPVRSAM SGASQPRGPA LLFPATRGVP AKRLLDADDA AAVAAKCPRL SECSSPPDYL
     SPPGSPCSPQ PPPAAPGAGG GSGSAPGPSR IADYLLLPLA EREHVSRALC IHTGRELRCK
     VFPIKHYQDK IRPYIQLPSH SNITGIVEVI LGETKAYVFF EKDFGDMHSY VRSRKRLREE
     EAARLFKQIV SAVAHCHQSA IVLGDLKLRK FVFSTEERTQ LRLESLEDTH IMKGEDDALS
     DKHGCPAYVS PEILNTTGTY SGKAADVWSL GVMLYTLLVG RYPFHDSDPS ALFSKIRRGQ
     FCIPEHISPK ARCLIRSLLR REPSERLTAP EILLHPWFES VLEPGYIDSE IGTSDQIVPE
     YQEDSDISSF FC
//
